P219 Prognostic potential of mucosal proteins in Ulcerative Colitis

B Salomon,M Carlson,D Bergemalm,C R H Hedin,J D Söderholm,Å V Keita,A Carsten,O Grip,J Marsal,C Eriksson,H Strid,C M Lindqvist,L Öhman,M K Magnusson,M D’Amato,D Repsilber,R Kruse,J Halfvarson

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0349

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Better prognostic measures for ulcerative colitis (UC) could significantly advance patient care. While the prognostic capacity of circulating proteins in UC has been explored, the role of mucosal proteins remains largely unknown. We examined mucosal protein markers in patients with incident ulcerative colitis and evaluated their prognostic value. Methods Biopsies from macroscopically inflamed colonic/rectal mucosa of adult patients in the Swedish inception cohort of IBD (SIC IBD) were obtained at diagnosis of UC. Patients were followed prospectively, and clinical data were recorded after 3 and 12 months. Disease course was categorised as indolent or aggressive at 12 months, based on a composite outcome of colectomy, hospital admission for active disease, treatment refractoriness towards ≥2 biological agents; the use of >2 courses of corticosteroids, or a cumulative dose of >2.5 g. Relative estimates of 162 protein markers were assessed in homogenised tissue supernatants, using proximity extension assay technology (Olink Proteomics, Uppsala, Inflammation and Oncology II panel). Mann-Whitney U test, with Benjamini-Hochberg correction was used to identify differentially regulated mucosal proteins in aggressive vs indolent disease course, with a 5% false discovery rate (FDR). Smoothly clipped absolute deviation regularised logistic regression models were used to identify prognostic signatures distinguishing aggressive from indolent disease course. Performance was estimated in a leave-one-out cross-validation and reported as the area under the receiver operating characteristic (ROC) curve (AUC). Results 117 patients provided a macroscopically inflamed colonic/rectal biopsy at diagnosis of UC. Basic demographics and clinical characteristics are presented in Table 1. Relative protein levels of WFdc2 and CCL20 were significantly lower in lysates from patients developing an aggressive course vs patients developing an indolent course, while estimates of MMP1, CCL11, WISP-1, OPG, RSPO3 and VEGFR2 were higher (Figure 1A). Regularized logistic regression identified signatures restricted to 28 proteins, distinguishing aggressive from indolent UC courses, yielding an AUC of 0.68 (95% confidence interval (CI): 0.56-0.80) for left-out samples (Figure 1B). Incorporating extent of inflammation at diagnosis in the model improved the AUC to 0.71 (95% CI: 0.60-0.83). Conclusion We identified prognostic mucosal protein signatures associated with future course of ulcerative colitis by analysing inflamed mucosal biopsies that were obtained at diagnosis. These protein markers may highlight pathways of relevance for ulcerative colitis outcomes.

gastroenterology & hepatology

What problem does this paper attempt to address?

This paper aims to address the issue of predicting the prognosis of patients with Ulcerative Colitis (UC). Although previous studies have explored the prognostic value of circulating proteins in UC, the role of mucosal proteins has not been fully understood. The research team evaluated the prognostic value of these mucosal protein markers by analyzing inflammatory mucosal biopsy samples from newly diagnosed UC patients.

Specifically, the researchers obtained biopsy samples of macroscopically inflamed colorectal mucosa from adult UC patients in the Swedish IBD inception cohort (SIC IBD) and sampled them at the time of diagnosis. Patients were then followed prospectively for 12 months, and clinical data were recorded. The disease course was classified as indolent or aggressive based on factors such as undergoing colectomy within 12 months post-diagnosis, hospitalization due to active disease, failure to respond to ≥2 biologic treatments, use of >2 courses of corticosteroids, or a cumulative dose >2.5g.

Using proximity extension assay, 162 protein markers were quantitatively detected, and statistical methods were employed to screen for differentially expressed mucosal proteins. A logistic regression model was then constructed to identify combinations of prognostic markers that could distinguish between aggressive and indolent UC courses. The results indicated that certain specific proteins (such as WFdc2 and CCL20) were significantly lower in aggressive UC patients compared to indolent patients, while other proteins (such as MMP1, CCL11, etc.) showed the opposite trend. Ultimately, the study identified a combination of 28 protein markers that demonstrated some prognostic capability in distinguishing aggressive from indolent UC (AUC=0.68). When the degree of inflammation at diagnosis was included in the model, the AUC increased to 0.71. These findings may help elucidate biological pathways associated with UC outcomes.